Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
February 9, 2021
Assignee:
LABORATOIRES MAJOR
Inventors:
Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
Abstract: Described are methods of treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway. The methods include identifying subjects in need of therapy, administering inhibitors of the Wnt/Frizzled signaling pathway, pharmaceutical compositions including the inhibitors, and methods of using the compounds and compositions for treating cancer, bacterial and viral infection, lupus, type II diabetes, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) in a subject.
Type:
Grant
Filed:
June 24, 2016
Date of Patent:
February 2, 2021
Assignee:
Duke University
Inventors:
Wei Chen, Robert A. Mook, Jr., Jiangbo Wang, Xiu-rong Ren, Minyong Chen, Lawrence S. Barak, Herbert Kim Lyerly, David Needham
Abstract: A method of and composition for treating a patient having Mycobacterium avium complex (MAC), and in one embodiment Mycobacterium avium subspecies paratuberculosis (MAP), causing one or more diseases, an embodiment of the method including administering to the patient an effective amount of one or more antibiotics and administering to the patient an effective amount of ultraviolet blood irradiation (UVBI) treatments, and an embodiment of the composition including an effective amount of one or more antibiotics and an effective amount of UVBI treated blood of the patient.
Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.
Type:
Grant
Filed:
December 31, 2018
Date of Patent:
January 19, 2021
Assignee:
AEROMICS, INC.
Inventors:
Marc F. Pelletier, Paul Robert McGuirk, George William Farr
Abstract: A dietary supplement composition provided synergistic effects of xanthorrhizol and tocotrienol on malignancies. A blend of xanthorrhizol and delta tocotrienol achieved 69% growth suppression of melanoma, exceeding the sum of individual effects. In prostate cancer, 90% growth suppression was achieved by a blend of xanthorrhizol and delta tocotrienol; however, the same 90% of growth suppression was achieved by 3-fold xanthorrhizol and 1.8-fold delta tocotrienol respectively, which indicated synergistic impact of the two agents. Mechanisms of action for the anticancer property showed synergism of xanthorrhizol and tocotrienol-mediated cancer growth suppression was attributed to cell cycle arrest, at the G1 phase of cell cycle, and apoptosis. This novel dietary supplement combination of xanthorrhizol to tocotrienol (1:1 to 10:1) may provide benefits to individuals consuming it on a regular or periodic basis.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
January 19, 2021
Assignee:
AMERICAN RIVER NUTRITION, LLC
Inventors:
Darren Heiy-Yin Chan, Chappell Rebecca Madhani, Manal Elfakhani, Sophie Thora Yount, Huanbiao Mo, Barrie Tan
Abstract: Compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, disclosed are combined therapies that modulate synapse function for treating the disease.
Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease with comorbid apathy comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.
Type:
Grant
Filed:
May 19, 2017
Date of Patent:
December 8, 2020
Assignee:
Azure Biotech, Inc.
Inventors:
Valerie Ceva, Steven R. Goldstein, Susan L. Levinson, David D. Thompson, Andreas Bernkop-Schnürch, Isabelle Nardin
Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
Abstract: A method for producing substantially pure levorphanol and related compounds, when compared to the conventional process, is provided. In particular, a method for producing substantially pure levorphanol tartrate dihydrate is described. Also described are compositions comprising levorphanol and related compounds, particularly compositions comprising levorphanol tartrate dihydrate, levomethorphan, and norlevorphanol in which the levomethorphan and norlevorphanol are present in the composition in reduced levels.
Type:
Grant
Filed:
October 4, 2018
Date of Patent:
December 1, 2020
Assignee:
AMPAC FINE CHEMICALS LLC
Inventors:
William Dubay, Alex Nichols, Wei Chen, Alec Brozell, Ajay Ryerson
Abstract: Described are methods of treating or preventing a bacterial infection by administering an antibacterial agent comprising a ?-lactamase inhibitor and one or more carbapenem to a subject.
Abstract: Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
Type:
Grant
Filed:
June 1, 2020
Date of Patent:
November 17, 2020
Assignee:
ORIC PHARMACEUTICALS, INC.
Inventors:
Daqing Sun, Lawrence R. McGee, Xiaohui Du, Liusheng Zhu, Xuelei Yan, Yosup Rew, John Eksterowicz, Julio C. Medina, Valeria R. Fantin, Haiying Zhou, Minna Delarae Balbas
Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, which composition has a surface tension of 40 dynes/cm or less and has continuing spreadability, and which composition is effective in treating a disorder of the nail or nail bed.
Abstract: The invention pertains to the use of therapeutically effective amounts of (i) vitamin A and/or functional equivalents, (ii) vitamin D and/or functional equivalents, and (iii) at least one omega-3 PUFA, preferably DHA and/or EPA, more preferably DHA and EPA, for the manufacture of a composition or medicament for treating, reducing and/or preventing neuroinflammation and/or symptoms associated with neuroinflammation in a subject in need thereof, as well as for reducing microglia activation, and/or for treating, reducing and/or preventing symptoms associated with excessive activation of microglia; and/or for reducing the secretion of inflammatory cytokines, preferably IL-6, and/or for treating, reducing and/or preventing symptoms associated with excessive secretion of inflammatory cytokines, in a subject in need thereof.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
November 3, 2020
Assignee:
N.V. Nutricia
Inventors:
Sofia Lopes Da Silva, Ladislaus Maria Broersen, Robert Johan Joseph Hageman, Jan Maarten Verkuijl
Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.
Abstract: The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.